Bryan Goodwin

69 papers receiving 13.8k citations

Bryan Goodwin's Hit Papers

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects 2016 · 413 citations
4130+9+18Years since publication50010001.5k

Peers

Bryan Goodwin
Comparison fields: 5 of 135
  • Pharmacology 4.7k
  • Oncology 6.0k
  • Endocrinology, Diabetes and Metabolism 2.2k
  • Hepatology 783
  • Biochemistry 622
Replace Stacey A. Jones with:
Stacey A. Jones United States
Linda B. Moore United States
John Y.L. Chiang United States
Erin G. Schuetz United States
Makoto Makishima Japan
Edward L. LeCluyse United States
Folkert Kuipers Netherlands
Dominique Pessayre France
Grace L. Guo United States
John T. Moore United States
Bryan Goodwin relative to Stacey A. Jones United States Stacey A. Jones's profile →
Citations per field
00.5×1.5×
Stacey A. Jones · 1×
Citations per year

Countries citing papers authored by Bryan Goodwin

Since Specialization
Citations

This map shows the geographic impact of Bryan Goodwin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bryan Goodwin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bryan Goodwin more than expected).

Fields of papers citing papers by Bryan Goodwin

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bryan Goodwin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bryan Goodwin. The network helps show where Bryan Goodwin may publish in the future.

Co-authors

The 25 scholars most cited alongside Bryan Goodwin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bryan Goodwin Line = papers co-authored together Bryan Goodwin links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 69 papers — load more, or switch the sort, to bring in the rest.

#Work
1
A Regulatory Cascade of the Nuclear Receptors FXR, SHP-1, and LRH-1 Represses Bile Acid Biosynthesis
Hit paper breakdown →
20001606
2
Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis
Hit paper breakdown →
20051482
3
The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity
Hit paper breakdown →
20011117
4
The Nuclear Pregnane X Receptor: A Key Regulator of Xenobiotic Metabolism
Hit paper breakdown →
2002740
5
Regulation of Multidrug Resistance-associated Protein 2 (ABCC2) by the Nuclear Receptors Pregnane X Receptor, Farnesoid X-activated Receptor, and Constitutive Androstane Receptor
Hit paper breakdown →
2002723
6
St. John's wort induces hepatic drug metabolism through activation of the pregnane X receptor
Hit paper breakdown →
2000709
7
Orphan Nuclear Receptors Constitutive Androstane Receptor and Pregnane X Receptor Share Xenobiotic and Steroid Ligands
Hit paper breakdown →
2000685
8
Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis
Hit paper breakdown →
2003562
9
The Orphan Human Pregnane X Receptor Mediates the Transcriptional Activation ofCYP3A4by Rifampicin through a Distal Enhancer Module
Hit paper breakdown →
1999559
10
Nuclear Pregnane X Receptor and Constitutive Androstane Receptor Regulate Overlapping but Distinct Sets of Genes Involved in Xenobiotic Detoxification
Hit paper breakdown →
2002554
11
A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects
Hit paper breakdown →
2016413
12 2003353
13 2003318
14 2001304
15 2002269
16 2015247
17 2005245
18 2002213
19 2004186
20 2005163

About Bryan Goodwin

Bryan Goodwin is a scholar working on Oncology, Pharmacology, Molecular Biology, Endocrinology, Diabetes and Metabolism and Surgery, having authored 69 papers that have together received 14.1k indexed citations. Recurring topics across this work include Drug Transport and Resistance Mechanisms (31 papers), Pharmacogenetics and Drug Metabolism (31 papers), Cholesterol and Lipid Metabolism (13 papers), Hormonal Regulation and Hypertension (13 papers), Estrogen and related hormone effects (13 papers), Liver Disease Diagnosis and Treatment (8 papers), Epigenetics and DNA Methylation (6 papers) and Lipid metabolism and biosynthesis (5 papers). The work is most often cited by research in Pharmacology (4.7k citations), Oncology (6.0k citations), Endocrinology, Diabetes and Metabolism (2.2k citations), Hepatology (783 citations) and Biochemistry (622 citations). Bryan Goodwin has collaborated with scholars based in United States, Australia and Netherlands. Frequent co-authors include Steven A. Kliewer, Timothy M. Willson, Stacey A. Jones, Linda B. Moore, Christopher Liddle, Jon L. Collins, David D. McKee, Guizhen Luo, Jodi M. Maglich and Michael A. Watson. Their work appears in journals such as Molecular Pharmacology, Journal of Biological Chemistry, Molecular Endocrinology, Proceedings of the National Academy of Sciences and Cell Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact